Global Neuroendocrine Tumor Market Size, Competitive Analysis, Share, Forecast- 2019-2025

1. Orion Market Research Global Neuroendocrine Tumor Market Size, Competitive Analysis, Share, Forecast- 2019-2025 Request a Free Sample @ https://www.omrglobal.com/request-sample/neuroendocrine- tumor-market Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404

2. The global neuroendocrine tumor market is projected to grow at a CAGR of around 10% during the forecast period. The market is studied on the basis of treatment type, indication, and end- user. Amongst the indication, the global neuroendocrine tumor market is segmented into the lungs, pancreas, gastrointestinal, and others. The gastrointestinal segment holds a significant share in the market. The segmental growth is attributed to the increased incidences of gastrointestinal diseases such as colon cancer, tumor in the intestine, and many others. The rising prevalence of several gastrointestinal diseases has been recorded globally. As per WHO, gastric cancer has been the fifth most common cancer globally in which malignant (cancer) cells form in the lining of the stomach. To @ https://www.omrglobal.com/request-sample/neuroendocrine-tumor-market learn more about this report request a free sample copy Smoking and ulcer are some major factors leading to gastric cancer. Additionally, other factors including age factor, diet, and stomach disease such as gastrointestinal reflux disease (GERD) can increase the risk of developing gastric cancer. Symptoms of gastric cancer include indigestion and stomach discomfort or pain. It has been noted that about 6 out of 10 people with the age of 65 years or older are expected to be diagnosed with gastric cancer. Additionally, the average risk of a person developing stomach cancer in their lifetime is about 1 in 111. Browse reports/neuroendocrine-tumor-market for Full Report Description@ https://www.omrglobal.com/industry- In the US, more than 26,240 incidences of gastric cancer were recorded in 2018 which is about 15% of all new cancer cases, according to the National Cancer Institute. The situations are more severe in Asian countries such as Japan and China. For instance, Japan has around 132,800 cases of stomach cancer in 2017. Similar trends were observed in China as around 498,000 gastric cancer deaths were recorded. Such an increasing number of cases increase the demand for better treatment options, which in turn, drive the growth of the global neuroendocrine tumor market. Global Neuroendocrine Tumor Market – Segmentation By Treatment Type Somatostatin Analogs (SSA) Targeted Therapy Chemotherapy Others By Indication

3. Lungs Pancreas Gastrointestinal Others By End-User Hospital& Clinics Others Global Neuroendocrine Tumor Market – Segmentation by Region North America United States Canada Europe Germany United Kingdom France Spain Italy Rest of Europe Asia-Pacific China Japan India Rest of Asia-Pacific Rest of the World Middle East & Africa Latin America Company Profiles AVEO Pharmaceuticals Inc. Boehringer Ingelheim International GmbH Bristol-Myers Squibb Co.

4. Dauntless Pharmaceuticals, Inc. Eli Lilly & Co. Exelixis, Inc. F. Hoffmann-La Roche Ltd. Hutchison MediTechLtd. Ipsen Group Mateon Therapeutics, Inc. Novartis International AG Pfizer Inc. Progenics Pharmaceuticals, Inc. Tarveda Therapeutics, Inc. Teva Pharmaceutical Industries, Ltd. For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/neuroendocrine-tumor-market About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404